Avacta Group (AVCT)


Latest News

Avacta in line with market forecasts

Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forec...

HardmanResearch: Affimer Drug Conjugates a reality

RNS Number: 8785B Avacta Group PLC 15 January 2018 Hardman Research: Affimer Drug Conjugates a reality Affimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which...

Avacta agrees development partnership with Glythera

Avacta Group and Glythera have agreed the terms of a licensing deal which will allow them to develop drug conjugates u...

Drug Development Partnership with Glythera

RNS Number: 7915B Avacta Group PLC 15 January 2018 15 January 2018 Avacta Group plc ("Avacta" or "the Group" or "the Company") Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership Successful proof-of-concept study leads to Affimer drug conjugate development partnership Affimers shown to have key ...

All News

18-01-18Avacta in line with market forecasts StockMarketWire
15-01-18HardmanResearch: Affimer Drug Conjugates a realityRNS
15-01-18Avacta agrees development partnership with Glythera StockMarketWire
15-01-18Drug Development Partnership with GlytheraRNS
08-01-18Avacta to host capital markets day StockMarketWire
08-01-18Capital Markets Day NotificationRNS
04-01-18PDMR Dealing and Issue of EquityRNS
03-01-18Avacta CEO to present at Biotech ShowcaseStockMarketWire
03-01-18Presenting at the Biotech Showcase, San FranciscoRNS
18-12-17Issue of EquityRNS
04-12-17Avacta schedules AGMStockMarketWire
04-12-17Posting of Annual Report and Notice of AGMRNS
30-11-17Avacta sets up SIP, issues sharesStockMarketWire
30-11-17Issue of EquityRNS
15-11-17Covance to present Affimer data at forum says AvactaStockMarketWire
15-11-17Covance to Present Affimer Data at ConferenceRNS
14-11-17Holding(s) in CompanyRNS
13-11-17Avacta to present at PEGS EuropeStockMarketWire
13-11-17Avacta to Present at Investor EveningRNS
13-11-17Avacta to present at PEGS EuropeRNS
24-10-17Record Year for Affimers in scientific publications, says Avacta StockMarketWire
24-10-17Affimers in Scientific PublicationsRNS
19-10-17Private Shareholder Update EventRNS
16-10-17Hardman Res.: R&D accelerated to advance assetsRNS
12-10-17Avacta to present at Shares Spotlight EveningStockMarketWire
12-10-17Avacta to Present at Shares Spotlight EveningRNS
10-10-17Avacta to present at the Shares Spotlight Evening in London on 19 October 2017StockMarketWire
10-10-17Avacta CTO to present at US conference StockMarketWire
10-10-17Avacta to Present at Major US ConferenceRNS
09-10-17Director Dealing and Issue of EquityRNS
05-10-17Avacta research collaboration with FIT BiotechStockMarketWire
05-10-17Research collaboration with FIT Biotech OyRNS
04-10-17Avacta revenues rise but losses widen StockMarketWire
04-10-17Preliminary ResultsRNS
02-10-17Avacta establishes US business development teamStockMarketWire
02-10-17Avacta establishes US business development teamRNS
07-09-17Notice of ResultsRNS
21-08-17Director Deals - Avacta Group PLC (AVCT)StockMarketWire
21-08-17Director/PDMR ShareholdingRNS
07-08-17Avacta revenues rise StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AVCT Editorial
  • Regulatory news feed for LSE:AVCT Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account